Results 281 to 290 of about 216,066 (333)

Phosphodiesterase inhibitors

2021
Cerebral ischemic diseases are among the most prevalent causes of death and the leading cause of adult disability worldwide. Although many studies have investigated the pathophysiological mechanisms involved in the cerebral ischemic injury, no effective pharmacological treatment has been established.
openaire   +1 more source

Novel Phosphodiesterase Inhibitors for Cognitive Improvement in Alzheimer's Disease.

Journal of Medicinal Chemistry, 2018
Yinuo Wu, Zhe Li, Yi-You Huang, Deyan Wu, Hai-bin Luo   +4 more
semanticscholar   +1 more source

Xanthines and Phosphodiesterase Inhibitors.

Handbook of Experimental Pharmacology, 2017
D. Spina, Clive P. Page
semanticscholar   +1 more source

Phosphodiesterases

2020
Moritz Helmstädter, Manfred Schubert-Zsilavecz   +1 more
openaire   +1 more source

Latest Evidence on the Use of Phosphodiesterase Type 5 Inhibitors for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia.

European Urology, 2016
M. Gacci, K. Andersson, C. Chapple, M. Maggi, V. Mirone, M. Oelke, H. Porst, C. Roehrborn, C. Stief, F. Giuliano   +9 more
semanticscholar   +1 more source

Phosphodiesterase 4A

2007
Marco Conti, S.-L. Catherine Jin, Joseph A. Beavo   +2 more
openaire   +1 more source

Tyrosyl-DNA phosphodiesterase inhibitors: Progress and potential.

Bioorganic & Medicinal Chemistry, 2016
S. S. Laev, N. Salakhutdinov, O. Lavrik
semanticscholar   +1 more source

Phosphodiesterase 1C

2007
Chen Yan, Joseph A. Beavo
openaire   +1 more source

Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy

Nature Medicine, 2005
E. Takimoto, H. Champion, Manxiang Li, Diego Belardi, Shuxun Ren, E. Rodriguez, D. Bedja, K. Gabrielson, Yibin Wang, D. Kass   +9 more
semanticscholar   +1 more source

Phosphodiesterase 7A

2007
Valeria Vasta, Joseph A. Beavo
openaire   +1 more source